Genolution

Genolution Current Liabilities

The Current Liabilities of Genolution (225220.KQ) as of Oct 22, 2026 is 423.21 M KRW. In the previous year, Current Liabilities was 5.27 B KRW — a change of -91.97% (lower).

Current Liabilities

423.21 MKRW

YoY

-91.97%

Last updated:

Current Liabilities of Genolution is 2025 423.21 M KRW. Current Liabilities of Genolution was 2024 5.27 B KRW. It decreases by -91.97% lower compared to the previous year.

The Genolution Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
3.45 B KRW
Jan 1, 2019
8.26 B KRW
Jan 1, 2020
15.84 B KRW
Jan 1, 2021
3.78 B KRW
Jan 1, 2022
2.28 B KRW
Jan 1, 2023
9.39 B KRW
Jan 1, 2024
5.27 B KRW
Jan 1, 2025
423.21 M KRW
The Genolution Current Liabilities history
YEARCurrent LiabilitiesYoY
423.21 MKRW-91.97%
5.27 BKRW-43.91%
9.39 BKRW+312.43%
2.28 BKRW-39.71%
3.78 BKRW-76.15%
15.84 BKRW+91.67%
8.26 BKRW+139.33%
3.45 BKRW—
0.00KRW—
0.00KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Current Liabilities of Genolution is 423.21 M KRW in 2025.

Current Liabilities of Genolution changed from 5.27 B KRW to 423.21 M KRW, representing a -91.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Genolution since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Genolution historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Genolution

All Key Metrics — Genolution